Transdermal application of myelin peptides in multiple sclerosis treatment

JAMA Neurology

Volumn 70, Issue 9, 2013, Pages 1105-1109

  Walczak, Agata ^a   Siger, Malgorzata ^a   Ciach, Agnieszka ^a   Szczepanik, Marian ^b   Selmaj, Krzysztof ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM; MYELIN BASIC PROTEIN; MYELIN BASIC PROTEIN 85-99; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN 35-55; PLACEBO; PROTEOLIPID PROTEIN; PROTEOLIPID PROTEIN 139-155; UNCLASSIFIED DRUG;

ADULT; APPLICATION SITE ERYTHEMA; APPLICATION SITE PRURITUS; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; IMMUNOTHERAPY; LACRIMATION DISORDER; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; RELAPSE; TRANSDERMAL PATCH; UPPER RESPIRATORY TRACT INFECTION;

EID: 84883780606     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2013.3022     Document Type: Article

References (27)

1. McFarland HF, Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol. 2007;8(9):913-919. (Pubitemid 47300005)
2. Bhat R, Steinman L. Innate and adaptive autoimmunity directed to the central nervous system. Neuron. 2009;64(1):123-132.
3. Codarri L, Fontana A, Becher B. Cytokine networks in multiple sclerosis: lost in translation. Curr Opin Neurol. 2010;23(3):205-211.
4. Franciotta D, Salvetti M, Lolli F, Serafini B, Aloisi F. B cells and multiple sclerosis. Lancet Neurol. 2008;7(9):852-858.
5. Hafler DA, Slavik JM, Anderson DE, O'Connor KC, De Jager P, Baecher-Allan C. Multiple sclerosis. Immunol Rev. 2005;204(1):208-231. (Pubitemid 40460504)
6. Brinkmann V, Billich A, Baumruker T, et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov. 2010;9(11):883-897.
7. Giacomini PS, Darlington PJ, Bar-Or A. Emerging multiple sclerosis disease-modifying therapies. Curr Opin Neurol. 2009;22(3):226-232.
8. Coles AJ, Wing MG, Molyneux P, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol. 1999;46(3):296-304. (Pubitemid 29416266)
9. Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases [published correction appears in Lancet Neurol. 2010;9(5):463]. Lancet Neurol. 2010;9(4):438-446.
10. Lindå H, von Heijne A, Major EO, et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med. 2009;361(11):1081-1087.
11. Muir VJ, Plosker GL. Cladribine tablets: in relapsing-remitting multiple sclerosis. CNS Drugs. 2011;25(3):239-249.
12. Lutterotti A, Sospedra M, Martin R. Antigen-specific therapies in MS: current concepts and novel approaches. J Neurol Sci. 2008;274(1-2):18-22.
13. Kaushansky N, Eisenstein M, Zilkha-Falb R, Ben-Nun A. Themyelin-associated oligodendrocytic basic protein (MOBP) as a relevant primary target autoantigen in multiple sclerosis. Autoimmun Rev. 2010;9(4):233-236.
14. Fissolo N, Haag S, de Graaf KL, et al. Naturally presented peptides on major histocompatibility complex I and II molecules eluted from central nervous system of multiple sclerosis patients. Mol Cell Proteomics. 2009;8(9):2090-2101.
15. Greer JM, Pender MP. Myelin proteolipid protein: an effective autoantigen and target of autoimmunity in multiple sclerosis. J Autoimmun. 2008;31(3):281-287.
16. Honma K, Parker KC, Becker KG, McFarland HF, Coligan JE, Biddison WE. Identification of an epitope derived from human proteolipid protein that can induce autoreactive CD8+ cytotoxic T lymphocytes restricted by HLA-A3: evidence for cross-reactivity with an environmental microorganism. J Neuroimmunol. 1997;73(1-2):7-14. (Pubitemid 27105264)
17. Zhang H, Podojil JR, Chang J, Luo X, Miller SD. TGF-beta-induced myelin peptide-specific regulatory T cells mediate antigen-specific suppression of induction of experimental autoimmune encephalomyelitis. J Immunol. 2010;184(12):6629-6636.
18. Bynoe MS, Evans JT, Viret C, Janeway CA Jr. Epicutaneous immunization with autoantigenic peptides induces T suppressor cells that prevent experimental allergic encephalomyelitis. Immunity. 2003;19(3):317-328. (Pubitemid 37153409)
19. Tutaj M, Szczepanik M. Epicutaneous (EC) immunization with myelin basic protein (MBP) induces TCRalphabeta+ CD4+ CD8+ double positive suppressor cells that protect from experimental autoimmune encephalomyelitis (EAE). J Autoimmun. 2007;28(4):208-215. (Pubitemid 46754767)
20. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol. 2005;58(6):840-846. (Pubitemid 41746873)
21. Harris JO, Frank JA, Patronas N, McFarlin DE, McFarland HF. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol. 1991;29(5):548-555.
22. Filippi M, Agosta F. Imaging biomarkers in multiple sclerosis. J Magn Reson Imaging. 2010;31(4):770-788.
23. Bynoe MS, Bonorino P, Viret C. Control of experimental autoimmune encephalomyelitis by CD4+ suppressor T cells: peripheral versus in situ immunoregulation. J Neuroimmunol. 2007;191(1-2):61-69. (Pubitemid 350061000)
24. Juryńczyk M, Walczak A, Jurewicz A, Jesionek-Kupnicka D, Szczepanik M, Selmaj K. Immune regulation of multiple sclerosis by transdermally appliedmyelin peptides. Ann Neurol. 2010;68(5):593-601.
25. Hafler DA, Kent SC, Pietrusewicz MJ, Khoury SJ, Weiner HL, Fukaura H. Oral administration of myelin induces antigen-specific TGF-beta 1 secreting T cells in patients with multiple sclerosis. Ann N Y Acad Sci. 1997;835:120-131. (Pubitemid 28046100)
26. Warren KG, Catz I, Wucherpfennig KW. Tolerance induction tomyelin basic protein by intravenous synthetic peptides containing epitope P85 VVHFFKNIVTP96 in chronic progressive multiple sclerosis. J Neurol Sci. 1997;152(1):31-38. (Pubitemid 27469708)
27. Genain CP, Abel K, Belmar N, et al. Late complications of immune deviation therapy in a nonhuman primate. Science. 1996;274(5295):2054-2057. (Pubitemid 27020694)